Detecting Barrett oesophagus using Cytosponge

Affiliations

Comment

Jordan Hindson. Nat Rev Gastroenterol Hepatol. 2020 Oct.

. 2020 Oct;17(10):596.

doi: 10.1038/s41575-020-00359-4.

No abstract available

Comment on

Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial.
Fitzgerald RC, di Pietro M, O'Donovan M, Maroni R, Muldrew B, Debiram-Beecham I, Gehrung M, Offman J, Tripathi M, Smith SG, Aigret B, Walter FM, Rubin G; BEST3 Trial team; Sasieni P. Fitzgerald RC, et al. Lancet. 2020 Aug 1;396(10247):333-344. doi: 10.1016/S0140-6736(20)31099-0. Lancet. 2020. PMID: 32738955 Free PMC article. Clinical Trial.

1. Fitzgerald R, et al. Cytosponge-trefoil factor 3 versus usual care to identify Barrett’s oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial. Lancet. 2020;396:333–344. doi: 10.1016/S0140-6736(20)31099-0. - DOI - PMC - PubMed